Genetic Chaos in Tumours Could Help Predict Chemo Response
News Aug 07, 2015
The scientists analysed several tumour samples taken from eight different oesophageal cancer patients before and after chemotherapy. For each tumour, they assessed whether particular genetic faults were present in all the samples from each patient, or in only a proportion of them.
They found that most tumours were made up of a patchwork of faults. The more complicated this patchwork and the greater the genetic differences within each tumour, the more aggressive the tumour and the less likely it was to respond well to cisplatin – a drug commonly used to treat oesophageal cancer.
Importantly, the cells within these more aggressive tumours were also prone to picking up additional faults following cisplatin exposure, suggesting that the chemotherapy itself was driving new mutations and genetic chaos in drug resistant tumours.
This knowledge could one day be used to identify groups of patients with more aggressive tumours that would benefit from different approaches, such as earlier surgery or combinations of ‘smart drugs’ that target specific faulty molecules within tumours.
Study leader Professor Charles Swanton from the UCL Cancer Institute and Francis Crick Institute, said: “Studies like this are edging us closer to being able to predict cancer’s ‘next move’, hopefully leading to sophisticated new treatment combinations that will outsmart the disease before it can really take hold. This will be particularly crucial for hard-to-treat cancers like oesophageal cancer, which has seen disappointingly little improvement in survival in recent decades.”
Dr Kat Arney, Cancer Research UK’s science information manager, said: “Oesophageal cancer claims nearly 8,000 lives every year and more than half of all patients die within twelve months of diagnosis, so we’re urgently investing in more research to understand the disease, detect it earlier and treat it more effectively. By understanding the genetic chaos that lies at the heart of these tumours, we hope to make a real difference to this stark statistic and keep many more families together for longer.”
Advanced Prostate Cancer: EMA Approves Abiraterone Combined With Hormone Therapy as First-line TreatmentNews
The prostate cancer drug abiraterone has been approved by the European Medicines Agency in combination with standard hormone therapy for use as a first-line treatment for advanced prostate cancer.READ MORE
Cancer Cells Prevent Immune Cells from Producing Cancer Killing ChemicalsNews
Researchers have identified a substance released by pancreatic cancer cells that protects them from attack by immune cells called macrophagesREAD MORE
What’s in Your Wheat? Sequencing One of the Most Complex Genomes Known to ScienceNews
The wheat genome sequences may help biologists not only better understand the evolutionary history of wheat, but also advance the quest for hardier, more pest- and drought-resistant wheat types to help feed the world’s growing population.READ MORE
Comments | 0 ADD COMMENT
3rd Annual NGS Data Analysis and Informatics Conference
Feb 08 - Feb 09, 2018
3rd Annual Genome Editing & Engineering Conference
Feb 08 - Feb 09, 2018